Overview
NICE is unable to make a recommendation about the use in the NHS of abatacept (Orencia) for treating psoriatic arthritis after DMARDs. This is because Bristol–Myers Squibb Pharmaceuticals Ltd did not provide an evidence submission.
Last reviewed: 13 March 2019
Next review: We will review this decision if the company decides to make a submission.